SIRT2 and neoplasm: Our study is the first to use a transgenic mouse model while controlling for the possibility that Sirt2 functions as both a tumor promotor and suppressor in vivo, which proved to be scientifically relevant, as the MRI data and histopathological investigation in our study indicate stark phenotypic differences due to the sustained loss of Sirt2.